NervGen Pharma Corp. (NGEN)Healthcare | Biotechnology | Vancouver, Canada | NasdaqCM
4.07 USD
-0.09
(-2.163%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.26 +0.19 (4.668%) ⇧ (April 17, 2026, 7:51 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:09 p.m. EDT
NGEN is a highly volatile biotech stock with a recent price dip, but it appears to be in a consolidation phase. The stock is trading below its 50-day average and has a negative forward PE, suggesting it's not yet profitable. The recent news about FDA alignment and potential milestones could be positive catalysts, but the stock's fundamentals are weak. The options activity indicates mixed sentiment, with some bullish and bearish positions. For short-term traders, the stock might offer a buying opportunity if there's a positive catalyst, but the long-term outlook remains uncertain due to its weak fundamentals and lack of dividends. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.235683 |
| MSTL | 0.243160 |
| AutoTheta | 0.531102 |
| AutoARIMA | 0.591654 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.241 |
| Market Cap | 329,388,672 |
| Forward P/E | -15.13 |
| Beta | 0.99 |
| Website | https://www.nervgen.com |
As of April 11, 2026, 4:09 p.m. EDT: Options speculators are showing mixed signals. For near-term expirations, there is a concentration of open interest and volume on the call side, particularly at the 7.5 strike, suggesting some bullish sentiment. However, the puts show a notable increase in volume and open interest at the 2.5 strike, indicating potential bearish sentiment or hedging. The overall IV levels are relatively low, which might suggest a lack of conviction in either direction. The presence of ATM anchors and top OI strikes implies that traders are closely watching the price movement around the current level, which could be a sign of uncertainty or anticipation for a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9530517 |
| Address1 | 112-970 Burrard Street |
| Address2 | Unit 1290 |
| All Time High | 6.3 |
| All Time Low | 0.55 |
| Ask | 4.12 |
| Ask Size | 1 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 323,800 |
| Average Daily Volume3 Month | 163,532 |
| Average Volume | 163,532 |
| Average Volume10Days | 323,800 |
| Beta | 0.988 |
| Bid | 4.12 |
| Bid Size | 1 |
| Book Value | -0.0287676 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.07 |
| Current Ratio | 1.155 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.25 |
| Day Low | 4.06 |
| Debt To Equity | 0.241 |
| Display Name | NervGen Pharma |
| Earnings Timestamp | 1,774,960,200 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -25,023,456 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.282 |
| Enterprise Value | 307,327,392 |
| Eps Current Year | -0.26333 |
| Eps Forward | -0.269 |
| Eps Trailing Twelve Months | -0.43 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.052 |
| Fifty Day Average Change | 0.018000126 |
| Fifty Day Average Change Percent | 0.0044422816 |
| Fifty Two Week Change Percent | 95.30517 |
| Fifty Two Week High | 6.3 |
| Fifty Two Week High Change | -2.23 |
| Fifty Two Week High Change Percent | -0.35396823 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 2.5700002 |
| Fifty Two Week Low Change Percent | 1.7133335 |
| Fifty Two Week Range | 1.5 - 6.3 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,554,298,200,000 |
| Float Shares | 68,911,827 |
| Forward Eps | -0.269 |
| Forward P E | -15.130113 |
| Free Cashflow | -6,288,927 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20743999 |
| Held Percent Institutions | 0.0001 |
| Implied Shares Outstanding | 80,930,872 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. |
| Long Name | NervGen Pharma Corp. |
| Market | us_market |
| Market Cap | 329,388,672 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_577702483 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -44,117,304 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 329,388,644 |
| Number Of Analyst Opinions | 6 |
| Open | 4.2 |
| Operating Cashflow | -19,499,212 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 778-731-1711 |
| Post Market Change | 0.19000006 |
| Post Market Change Percent | 4.668306 |
| Post Market Price | 4.26 |
| Post Market Time | 1,776,469,869 |
| Previous Close | 4.16 |
| Price Eps Current Year | -15.455892 |
| Price Hint | 4 |
| Price To Book | -141.4786 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.123 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.0899997 |
| Regular Market Change Percent | -2.16345 |
| Regular Market Day High | 4.25 |
| Regular Market Day Low | 4.06 |
| Regular Market Day Range | 4.06 - 4.25 |
| Regular Market Open | 4.2 |
| Regular Market Previous Close | 4.16 |
| Regular Market Price | 4.07 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 102,819 |
| Return On Assets | -0.73424006 |
| Return On Equity | -14.57572 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 80,930,871 |
| Shares Percent Shares Out | 0.0176 |
| Shares Short | 1,350,054 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,309,036 |
| Short Name | NervGen Pharma Corp. |
| Short Ratio | 11.92 |
| Source Interval | 15 |
| State | BC |
| Symbol | NGEN |
| Target High Price | 18.0 |
| Target Low Price | 4.34 |
| Target Mean Price | 8.845 |
| Target Median Price | 6.85 |
| Total Cash | 22,069,636 |
| Total Cash Per Share | 0.273 |
| Total Debt | 8,369 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.490045 |
| Two Hundred Day Average Change | 0.5799551 |
| Two Hundred Day Average Change Percent | 0.1661741 |
| Type Disp | Equity |
| Volume | 102,819 |
| Website | https://www.nervgen.com |
| Zip | V6Z 2R4 |